Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 9/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165536 | 0.90 | PTPN11 (0.51) | PTPN11MAP3K11PIK3CAPIK3CDMTOR | |
| SCHEMBL7517481 | 0.87 | PTPN11 (0.49) | PTPN11MAP3K11TGFBR1LRRK2DYRK1A | |
| SCHEMBL30280395 | 0.86 | PTPN11 (0.51) | PTPN11MAP3K11TGFBR1LRRK2DYRK1A | |
| SCHEMBL721797 | 0.86 | PTPN11 (0.51) | PTPN11MAP3K11TGFBR1LRRK2DYRK1A | |
| SCHEMBL7907745 | 0.83 | PTPN11 (0.50) | PTPN11MAP3K11PIK3CAPIK3CDMTOR | |
| SCHEMBL15171430 | 0.83 | MAP3K11 (0.48) | PTPN11MAP3K11LRRK2CYP3A4CYP2D6 | |
| SCHEMBL15171450 | 0.83 | PTPN11 (0.46) | PTPN11MAP3K11TGFBR1LRRK2CYP3A4 | |
| SCHEMBL7899790 | 0.80 | PTPN11 (0.47) | PTPN11MAP3K11TGFBR1LRRK2DYRK1A | |
| SCHEMBL721859 | 0.80 | PTPN11 (0.47) | PTPN11MAP3K11TGFBR1LRRK2DYRK1A | |
| SCHEMBL7899740 | 0.79 | MAP3K11 (0.56) | PTPN11MAP3K11LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| EP-2925319-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | University Of Rochester (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846909-B2 | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014085795-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIVERSITY OF ROCHESTER (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2576549-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | University of Rochester (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | PTPN11 1325/4885MAP3K11 25/4885PIK3CA 216/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | PTPN11 1949/4885MAP3K11 45/4885PIK3CA 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.